David Harlan to Tacrolimus
This is a "connection" page, showing publications David Harlan has written about Tacrolimus.
Connection Strength
0.365
-
Hirshberg B, Rother KI, Digon BJ, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003 Dec; 26(12):3288-95.
Score: 0.223
-
Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression. J Clin Endocrinol Metab. 2002 Dec; 87(12):5424-9.
Score: 0.052
-
Montgomery SP, Mog SR, Xu H, Tadaki DK, Hirshberg B, Berning JD, Leconte J, Harlan DM, Hale D, Kirk AD. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant. 2002 Apr; 2(4):381-5.
Score: 0.050
-
Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999 Jun; 5(6):686-93.
Score: 0.041